Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Intersect ENT
In the third quarter of 2021, medical device company M&A values reached $7.1bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $6.7bn.
The company reported its progress in key environmental, social, and governance areas over the past year along with some new performance targets related to sustainability and inclusion. Medtronic also added a new “tagline” to its brand.
Medtronic announced plans to acquire Intersect ENT, adding its sinus implants to Medtronic's portfolio of devices used by surgeons in treating chronic rhinosinusitis.
A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. The week of July 23 to 29 was another slow one for FDA approvals, with no new PMAs, panel-track PMA supplements, de novos, or non-US approvals.
- Site Specific
- Drug Delivery
- Implantable Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Other Names / Subsidiaries
- Fiagon AG Medical Technologies